Biotech Firms Hide Early Research From Public View
U.S. biotechnology companies are withholding early-stage discoveries from disclosure, citing fears that Chinese firms will exploit them first.
Updated on Nov. 17, 2026 in Biotech

Live Poll
Should U.S. drug companies keep new research secret to protect against China?
Several U.S. biotechnology companies have adopted a policy of withholding early-stage research data from public disclosure, and scientists have stopped presenting posters and attending meetings to avoid sharing discoveries. Alnylam Pharmaceuticals maintains an unwritten policy against revealing early-stage studies, and Strand Therapeutics delays patent filings to keep discoveries secret.
Why it matters
Companies fear Chinese firms will seize U.S. biotech discoveries and quickly reach market with similar inventions or slightly altered versions, diluting the exclusivity of U.S. products. The shift means less early-stage scientific information is available to the broader research community.
The reporting describes qualitative practices rather than measured counts, so the number of affected firms and the scale of withheld research are not established. What remains unknown is whether the secrecy measurably reduces the flow of published biotech research.
The players
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a Cambridge, Massachusetts biotechnology company known for developing RNA interference therapeutics.
Curie.Bio
Curie.Bio is a biotechnology company whose co-founder Alexis Borisy has advised scientists to curb publishing and public presentations.
The details
Alnylam Pharmaceuticals follows an unwritten policy against revealing early-stage studies or discussing unpublished data. Strand Therapeutics delays patent filings to keep discoveries hidden, and Curie.Bio co-founder Alexis Borisy has told scientists to stop publishing, presenting posters, and attending meetings.
Big Picture
The shift departs from the tradition of open biomedical publication and poster presentation that long shaped U.S. biotech research sharing. It reflects a new competitive posture in which companies treat early discoveries as assets to protect from Chinese competitors.
Patients and clinicians may see new treatments reach the market later, since less early research is shared publicly. Researchers at smaller institutions could have less access to early findings that would otherwise inform their own work.
The takeaway
Secrecy around early biotech research trades open scientific exchange for competitive protection against foreign rivals. Readers should watch whether this practice slows the pace of medical discovery that depends on shared early findings.
Further reading
For more on the sector, explore Biotech coverage.
Source note: This article includes information reported by The New York Times.
Live Poll
Should U.S. drug companies keep new research secret to protect against China?






